A Treatment by a Bile Duct Stent Obtaining High Efficacy: Katsuhisa Enomoto, Sadao Amano and Kenichi Sakurai (Division of Breast and Breast cancer hepatic metastasis with icterus is poor in prognosis and an active treatment is hardly performed. However, we improved patients' QOL by inserting a bile duct stent as a topical treatment. CASE 1: A 63-year-old woman was seen having left breast cancer. We performed a modified radical mastectomy and axillary lymph node in January 1989. Since then, we continued chemotherapy and hormonal therapy. In the 16th year after the operation, we confirmed a liver functional impairment and saw an increase in T-Bil to be 5.5 mg/dl. We also confirmed multiple hepatic metastases and intrahepatic bile duct dilation. We detained a bile duct stent and performed a treatment to decrease the icterus. It has been three months since the insertion of the stent, but we have not confirmed the rise of T-Bil. CASE 2: A 49-year-old woman was seen having right breast cancer. We performed a modified radical mastectomy in June 2000. We confirmed multiple hepatic metastases in October 2005 and inserted a bile duct stent because we detected an expansion of the intrahepatic bile duct. In conclusion, it appears that a bile duct stent has improved patients' QOL in the cases where obstructive jaundice developed with breast cancer hepatic metastasis.